INSULINORESISTANCE IN PATIENTS WITH MASTOPATHY AND ITS EFFECT ON THE CLINICAL COURSE OF MASTOPATHY

Аннотация

Mastopathy is the most common disease in women, accounting for 90% of all mammalian diseases. The etiology of fibrous cystic mastopathy has not been fully elucidated, but many studied risk factors include endocrine disorders, particularly insulin resistance and thyroid disease. The goal. To study the effect of metformin on the incidence of insulin resistance and the clinical course of mastopathy in patients with FCM. Research sources and methods. The source of the study was 71 women of childbearing age (18-49) treated on the basis of the Urgench branch of the Tashkent Medical Academy on the basis of a diagnosis of fibrous cystic mastopathy. The mean age of the patients was 34.2 ± 0.4 years. Patients had an average body mass index of 31.4 ± 2.54 kg / m2 and a NOMA index of 3.2 ± 0.25. All women underwent breast and thyroid ultrasound (UTT) using a 7.5 mHz MINDRAY DC 60 (Japan) ultrasound machine. Conclusion. There is a strong correlation between decreased insulin resistance and the clinical course of mastopathy (r≤0.001). There is a reliable correlation between metformin intake in women with insulin-resistant mastopathy and a decrease in UTT BIRADS category (r≤0.05).